
    
      This is a randomized, 2-arm, parallel group, open-label study to evaluate the safety and
      efficacy of TA-7284 in Japanese patients with Type 2 diabetes mellitus, who are not optimally
      controlled on diet and exercise or with oral anti-hyperglycaemic agent. The patients will
      receive either TA-7284-Low or TA-7284-High orally alone or in combination with oral
      anit-hyperglycaemic agent for 52 weeks.
    
  